MedTrace Logo

Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia

NCT07166835 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-09-10

No results posted yet for this study

Summary

This study investigates the cognitive effects of Ārepa, a blackcurrant-based drink, under simulated high-altitude conditions (4,500m normobaric hypoxia for \~180 minutes). Using a double-blind, randomised, placebo-controlled crossover design, participants will consume either the nootropic blackcurrant-based drink or a taste-matched placebo. Cognitive testing (\~80 minutes) includes Trail-making, Stroop, N-back, Serial 7s/3s, and RVIP tasks. Physiological measures (heart rate, SpO₂, blood) and biomarkers (MAO-B, BDNF, hsCRP, S100B, Prolactin, C3G, Sarmentosin) will be assessed. Scales will evaluate mood, wellbeing, and perceived effects. The aim is to determine if the nootropic drink can support cognitive function in hypoxic environments.

Conditions

  • Cognitive Performance
  • Executive Function (Cognition)
  • Working Memory
  • Hypoxia Induced Cognitive Impairment
  • Mood

Interventions

DIETARY_SUPPLEMENT

Nootropics (ginkgo biloba, nicergoline, piracetam, or others)

Nootropic drink containing Anthrocyanins, L-theanie and Enzogenol

DIETARY_SUPPLEMENT

Placebo

Taste- and appearance-matched placebo beverage without active ingredients.

Sponsors & Collaborators

  • Leeds Beckett University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2025-12-25
Completion
2027-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166835 on ClinicalTrials.gov